Your browser is no longer supported. Please, upgrade your browser.
Applied Molecular Transport Inc.
Index- P/E- EPS (ttm)-1.97 Insider Own24.50% Shs Outstand35.20M Perf Week-19.01%
Market Cap1.60B Forward P/E- EPS next Y-2.84 Insider Trans0.10% Shs Float24.54M Perf Month-20.22%
Income-66.60M PEG- EPS next Q-0.75 Inst Own63.90% Short Float8.40% Perf Quarter15.40%
Sales- P/S- EPS this Y-236.20% Inst Trans0.07% Short Ratio6.93 Perf Half Y44.24%
Book/sh3.74 P/B11.88 EPS next Y-15.90% ROA-53.40% Target Price77.25 Perf Year-
Cash/sh3.61 P/C12.29 EPS next 5Y38.70% ROE-74.00% 52W Range17.05 - 78.22 Perf YTD44.43%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.19% Beta-
Dividend %- Quick Ratio17.20 Sales past 5Y- Gross Margin- 52W Low160.72% ATR5.91
Employees80 Current Ratio17.20 Sales Q/Q- Oper. Margin- RSI (14)43.38 Volatility12.94% 11.48%
OptionableYes Debt/Eq0.00 EPS Q/Q37.40% Profit Margin- Rel Volume1.08 Prev Close49.91
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume297.61K Price44.44
Recom1.20 SMA20-6.73% SMA50-18.00% SMA20019.08% Volume320,001 Change-10.96%
Mar-17-21Initiated JMP Securities Mkt Outperform $92
Jun-30-20Initiated SVB Leerink Outperform $32
Jun-30-20Initiated Jefferies Buy $38
Jun-30-20Initiated BofA Securities Buy $34
May-06-21 08:00AM  
Apr-27-21 03:17PM  
Apr-08-21 01:08AM  
Apr-06-21 04:01PM  
Mar-31-21 08:45PM  
Mar-29-21 04:11PM  
Mar-22-21 08:00AM  
Mar-19-21 04:05PM  
Mar-13-21 06:56AM  
Mar-09-21 08:00AM  
Mar-04-21 11:30PM  
Mar-01-21 08:00AM  
Feb-17-21 08:00AM  
Jan-19-21 08:00AM  
Dec-05-20 01:24AM  
Nov-24-20 08:00AM  
Nov-12-20 04:05PM  
Nov-11-20 08:00AM  
Nov-10-20 08:00AM  
Sep-22-20 08:00AM  
Sep-06-20 09:35AM  
Aug-27-20 08:00AM  
Aug-11-20 04:00PM  
Aug-05-20 08:00AM  
Jun-16-20 08:13AM  
Jun-09-20 04:05PM  
Jun-04-20 10:40PM  
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bhatt ElizabethChief Bus. & Strategy OfficerApr 21Option Exercise4.619,00041,4909,000Apr 22 06:29 PM
Bhatt ElizabethChief Bus. & Strategy OfficerApr 21Sale40.519,000364,5570Apr 22 06:29 PM
Kanwar BittooChief Medical OfficerApr 07Option Exercise2.387,50017,8507,500Apr 08 09:15 PM
Kanwar BittooChief Medical OfficerApr 07Sale54.797,500410,9460Apr 08 09:15 PM
Lamond DavidDirectorApr 06Buy42.0025,0001,050,0001,011,019Apr 07 06:47 PM
Kim Helen SusanDirectorJul 02Option Exercise0.02800,00016,000800,000Jul 06 05:41 PM